Compare ATLX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | KRRO |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Brazil | United States |
| Employees | 64 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 150.0M |
| IPO Year | 2012 | 2019 |
| Metric | ATLX | KRRO |
|---|---|---|
| Price | $4.22 | $13.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $12.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 1.0M | 114.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $92,491.00 | ★ $6,392,000.00 |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $3.60 | $5.20 |
| 52 Week High | $8.25 | $55.89 |
| Indicator | ATLX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 58.48 |
| Support Level | $3.97 | $9.51 |
| Resistance Level | $5.12 | $14.52 |
| Average True Range (ATR) | 0.35 | 0.95 |
| MACD | -0.10 | 0.32 |
| Stochastic Oscillator | 6.91 | 85.42 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.